Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
Authors
Keywords
Cancer treatment, Melanomas, Phase II clinical investigation, Cutaneous melanoma, Adverse events, Metastasis, Cancer chemotherapy, Oncology
Journal
PLoS One
Volume 10, Issue 3, Pages e0118564
Publisher
Public Library of Science (PLoS)
Online
2015-03-12
DOI
10.1371/journal.pone.0118564
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
- (2015) Kristina Buder et al. Cancer Medicine
- Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
- (2014) S. Leyvraz et al. ANNALS OF ONCOLOGY
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
- (2013) Sander Kelderman et al. ACTA ONCOLOGICA
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
- (2013) K G Griewank et al. BRITISH JOURNAL OF CANCER
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Treatment of metastatic uveal melanoma with intravenous fotemustine
- (2013) Francesco Spagnolo et al. MELANOMA RESEARCH
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Ipilimumab activity in advanced uveal melanoma
- (2012) Muhammad Adnan Khattak et al. MELANOMA RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
- (2012) Shailender Bhatia et al. PLoS One
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uveal Melanoma: Trends in Incidence, Treatment, and Survival
- (2011) Arun D. Singh et al. OPHTHALMOLOGY
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma
- (2010) Jade Homsi et al. MELANOMA RESEARCH
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Effectiveness of Treatments for Metastatic Uveal Melanoma
- (2009) James J. Augsburger et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
- (2009) K. S. Peggs et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now